CXCL1, C-X-C motif chemokine ligand 1, 2919

N. diseases: 315; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Secondary malignant neoplasm of peritoneum
0.010 Biomarker disease BEFREE <b>Conclusion:</b> This study highlights the significance of GRO-α and IL-8 as the key chemokines in the peritoneal tumor microenvironment and suggests the utility of targeting their receptor CXCR2 as a potential target-based therapy for peritoneal metastases of ovarian cancer. 29507619 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.100 Biomarker group BEFREE <b>Conclusions</b> High CXCL1 expression is a risk factor for cancer prognosis indicating a poor OS, and advanced TNM stage and lymph node metastasis, demonstrating that it may be a promising prognostic biomarker for different cancers. 31387444 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker group BEFREE <b>Conclusions</b> High CXCL1 expression is a risk factor for cancer prognosis indicating a poor OS, and advanced TNM stage and lymph node metastasis, demonstrating that it may be a promising prognostic biomarker for different cancers. 31387444 2019
Secondary malignant neoplasm of lymph node
0.060 Biomarker disease BEFREE <b>Conclusions</b> High CXCL1 expression is a risk factor for cancer prognosis indicating a poor OS, and advanced TNM stage and lymph node metastasis, demonstrating that it may be a promising prognostic biomarker for different cancers. 31387444 2019
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.010 Biomarker group BEFREE <b>Principal conclusions</b>: Taken together, our results argue that CXCL1 plays an important role in sustaining the growth of bladder and prostate tumors via up-regulation of IL6 and down-regulation of TIMP4. 30809313 2019
CUI: C0242852
Disease: Proliferative vitreoretinopathy
Proliferative vitreoretinopathy
0.020 Biomarker disease BEFREE <i>Purpose</i>: Comparison of IL-6 and CXCL-1 concentrations and CXCL-1/IL-6 ratio correlations with clinical parameters (RRD extent, duration, and proliferative vitreoretinopathy - PVR-grade) between subretinal fluid (SRF) and vitreous during rhegmatogenous retinal detachment (RRD) complicated with PVR.<i>Methods</i>: A total of 71 eyes of 71 patients with primary RRD possibly complicated with PVR were included; 36 eyes treated with scleral buckling and 35 eyes with pars-plana vitrectomy. 31661651 2019
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.010 Biomarker disease BEFREE (2018) generate a library of clonal PDAC tumors to examine the tumor-intrinsic features shaping the anti-tumor immune response and find that tumor cell-derived CXCL1 directly blunts T cell infiltration and reduces responsiveness to immunotherapy. 30021140 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE (2018) generate a library of clonal PDAC tumors to examine the tumor-intrinsic features shaping the anti-tumor immune response and find that tumor cell-derived CXCL1 directly blunts T cell infiltration and reduces responsiveness to immunotherapy. 30021140 2018
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease
0.010 Biomarker disease BEFREE (b) In platelets, ox-LDL induced release of ENA-78 and, when combined with SFLLRN, also of GRO-alpha, with significantly higher response in CAD. 12871498 2003
CUI: C0030193
Disease: Pain
Pain
0.060 AlteredExpression phenotype BEFREE 4-Methylbenzenecarbothioamide, a hydrogen sulfide donor, inhibits tumor necrosis factor-α and CXCL1 production and exhibits activity in models of pain and inflammation. 31132352 2019
Secondary malignant neoplasm of lung
0.020 AlteredExpression disease BEFREE 5-FU-mediated augmented lung metastasis was associated with increases in intrapulmonary neutrophil numbers and expression of neutrophilic chemokines, Cxcl1 and Cxcl2 in tumor cells, with few effects on intrapulmonary T-cell or macrophage numbers. 29643149 2018
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute
0.010 Biomarker disease BEFREE Acute myeloid leukaemia (AML) cells show constitutive release of several chemokines that occurs in three major clusters: (I) chemokine (C-C motif) ligand (CCL)2-4/chemokine (C-X-C motif) ligand (CXCL)1/8, (II) CCL5/CXCL9-11 and (III) CCL13/17/22/24/CXCL5. 19388934 2009
CUI: C0025202
Disease: melanoma
melanoma
0.100 Biomarker disease BEFREE Melanoma cell lines were positive for MGSA protein in both the presence and the absence of serum. 2095366 1990
Secondary malignant neoplasm of lymph node
0.060 AlteredExpression disease BEFREE Lymph node metastasis and peritoneal cytology positivity were correlated with high expression of CXCL1 and CXCL7. 31810929 2019
Infection caused by Helicobacter pylori
0.010 AlteredExpression disease BEFREE H pylori infection is associated with increased expression rates and production of C-X-C chemokines (IL-8 and GRO alpha), but not with increased production of C-C chemokines. 9659152 1998
CUI: C0003873
Disease: Rheumatoid Arthritis
Rheumatoid Arthritis
0.030 Biomarker disease BEFREE GRO-alpha was significantly higher in RA than in OA and PT patients. 10229398 1999
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis
0.030 Biomarker disease BEFREE GRO-alpha was significantly higher in RA than in OA and PT patients. 10229398 1999
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 AlteredExpression group BEFREE GRO alpha expression was evaluated in the tumour specimens compared with normal, while there was constitutive expression of GRO gamma in both normal and neoplastic colonic mucosa. 1341267 1992
Secondary malignant neoplasm of lymph node
0.060 AlteredExpression disease BEFREE GRO-1 expression was also associated with leukocyte infiltration, and lymph node metastasis. 15218300 2004
Malignant neoplasm of colon and/or rectum
0.060 Biomarker disease BEFREE CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. 16567391 2006
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE GRO-alpha is a CXC chemokine with tumor-associated angiogenic as well as oncogenic activation following ligation of its CXCR2 receptor. 16618733 2006
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE CXCL1/2 attract CD11b(+)Gr1(+) myeloid cells into the tumor, which produce chemokines including S100A8/9 that enhance cancer cell survival. 22770218 2012
CUI: C0040021
Disease: Thromboangiitis Obliterans
Thromboangiitis Obliterans
0.010 AlteredExpression disease BEFREE CXCL1 expression was significantly higher in the TAO patients than control subjects. 23567329 2014
CUI: C1402315
Disease: Vascular lesions
Vascular lesions
0.010 Biomarker disease BEFREE CXCL1-inhibting agents such as endostatin may constitute a useful approach to treat the malignant or intermediate vascular lesions. 25175281 2015
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.040 Biomarker disease BEFREE CXCL1 functions through CXCR2, a G protein-coupled receptor that transactivates EGFR in ovarian and lung cancers. 26462152 2015